Saphenous vein graft intervention.

[1]  J. Segal,et al.  Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. , 2011, Journal of the American College of Cardiology.

[2]  G. Stone,et al.  5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. , 2011, JACC. Cardiovascular interventions.

[3]  M. Leesar,et al.  Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: A comprehensive meta‐analysis of randomized trials and observational studies comprising 7,994 patients , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  J. D. de Lemos,et al.  Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. , 2011, JACC. Cardiovascular interventions.

[5]  A. Colombo,et al.  Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. , 2010, The American journal of cardiology.

[6]  D. Mukherjee,et al.  Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis. , 2010, JACC. Cardiovascular interventions.

[7]  J. Dery,et al.  Drug-Eluting or Bare Metal Stents for the Treatment of Saphenous Vein Graft Disease: A Bayesian Meta-Analysis , 2010, Circulation. Cardiovascular interventions.

[8]  G. Stone,et al.  Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). , 2010, The American journal of cardiology.

[9]  Sunil V. Rao,et al.  Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. , 2010, JACC. Cardiovascular interventions.

[10]  G. Biondi-Zoccai,et al.  Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  E. Mahmud,et al.  Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry). , 2010, The American journal of cardiology.

[12]  E. Mahmud,et al.  Impact of chronic renal insufficiency on clinical outcomes in patients undergoing saphenous vein graft intervention with drug‐eluting stents: A multicenter Southern Californian Registry , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  R. Costa,et al.  Preliminary results of the INSPIRE trial with the novel MGuard™ stent system containing a protection net to prevent distal embolization , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  M. Shishehbor,et al.  Drug-Eluting versus Bare-Metal Stent for Treatment of Saphenous Vein Grafts: A Meta-Analysis , 2010, PloS one.

[15]  J. López-Sendón,et al.  Safety and efficacy of drug-eluting stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis. , 2010 .

[16]  E. Mahmud,et al.  Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention. , 2010, The American journal of cardiology.

[17]  G. Dagenais,et al.  PLAQUE SEALING WITH PACLITAXEL-ELUTING STENTS FOR THE TREATMENT OF MODERATE NON-SIGNIFICANT SAPHENOUS VEIN GRAFT LESIONS. THREE-YEAR FOLLOW-UP OF THE VELETI (MODERATE VEIN GRAFT LESION STENTING WITH THE TAXUS STENT AND INTRAVASCULAR ULTRASOUND) TRIAL , 2010 .

[18]  K. Filion,et al.  Effectiveness and safety of drug-eluting stents in vein grafts: a meta-analysis. , 2010, American heart journal.

[19]  M. Jeong,et al.  Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. , 2010, The American journal of cardiology.

[20]  A. Shroyer,et al.  On-pump versus off-pump coronary-artery bypass surgery. , 2009, The New England journal of medicine.

[21]  G. Dagenais,et al.  Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial , 2009, Circulation.

[22]  Peter L Duffy,et al.  Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. , 2009, JACC. Cardiovascular interventions.

[23]  Subhash Banerjee,et al.  Clinical ResearchInterventional CardiologyA Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) Trial , 2009 .

[24]  A. Kirtane,et al.  Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE substudy. , 2008, JACC. Cardiovascular interventions.

[25]  A. J. O’Malley,et al.  Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients , 2008, Circulation.

[26]  C. Rogers,et al.  The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. , 2007, Journal of the American College of Cardiology.

[27]  S. Dixon,et al.  Embolic protection of saphenous vein graft percutaneous interventions. , 2007, Journal of interventional cardiology.

[28]  Pierfrancesco Agostoni,et al.  Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. , 2007, Journal of the American College of Cardiology.

[29]  T. Fischell,et al.  "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. , 2007, The Journal of invasive cardiology.

[30]  N. Bruining,et al.  Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. , 2006, Journal of the American College of Cardiology.

[31]  N. Weissman,et al.  Pivotal, randomized U.S. study of the Symbiot™ covered stent system in patients with saphenous vein graft disease: Eight‐month angiographic and clinical results from the Symbiot III trial , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[32]  C. O'shaughnessy,et al.  Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[33]  C. Rogers,et al.  Devices for distal protection during percutaneous coronary revascularization. , 2006, Circulation.

[34]  G. Stone,et al.  Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. , 2006, American heart journal.

[35]  G. Stone,et al.  Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. , 2006, European heart journal.

[36]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[37]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[38]  L. Liao,et al.  Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. , 2005, The American journal of cardiology.

[39]  J. Carrozza,et al.  Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. , 2005, Journal of the American College of Cardiology.

[40]  K. Kent,et al.  Bivalirudin versus heparin as an antithrombotic agent in patients who undergo percutaneous saphenous vein graft intervention with a distal protection device. , 2005, The American journal of cardiology.

[41]  D. Baim,et al.  Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. , 2005, The American journal of cardiology.

[42]  Robert J Anderson,et al.  Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. , 2004, Journal of the American College of Cardiology.

[43]  P. Widimsky,et al.  One-Year Coronary Bypass Graft Patency: A Randomized Comparison Between Off-Pump and On-Pump Surgery Angiographic Results of the PRAGUE-4 Trial , 2004, Circulation.

[44]  N. Smedira,et al.  Radial Artery Bypass Grafts Have an Increased Occurrence of Angiographically Severe Stenosis and Occlusion Compared With Left Internal Mammary Arteries and Saphenous Vein Grafts , 2004, Circulation.

[45]  G. Stankovic,et al.  Interventional cardiology: abstractRandomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the randomized evaluation of polytetrafluoroethylene COVERed stent in saphenous vein grafts (RECOVERS) trial☆ , 2003 .

[46]  K. Kent,et al.  Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. , 2003, American heart journal.

[47]  G. Stone,et al.  Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.

[48]  B. Gersh,et al.  Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. , 2003, The American journal of cardiology.

[49]  N. Weissman,et al.  Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. , 2003, American heart journal.

[50]  Deepak L. Bhatt,et al.  Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts: A Pooled Analysis of Five Randomized Clinical Trials , 2002, Circulation.

[51]  Jerome Sacks,et al.  Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. , 2002, Journal of the American College of Cardiology.

[52]  C. Gibson,et al.  Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. , 2002, The Journal of invasive cardiology.

[53]  G. Stone,et al.  Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. , 2002, The American journal of cardiology.

[54]  M. Leon,et al.  Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts , 2002, Circulation.

[55]  S. Sdringola,et al.  Risk assessment of slow or no‐reflow phenomenon in aortocoronary vein graft percutaneous intervention , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[56]  L. Liao,et al.  Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. , 2001, Journal of the American College of Cardiology.

[57]  G. Stone,et al.  Influence of gender on early and one-year clinical outcomes after saphenous vein graft stenting. , 2001, The American journal of cardiology.

[58]  S. Sdringola,et al.  Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow‐no reflow phenomenon , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[59]  G. Stone,et al.  Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. , 1999, Circulation.

[60]  T. Ryan,et al.  Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996. Northern New England Cardiovascular Disease Study Group. , 1999, Journal of the American College of Cardiology.

[61]  A. Carter,et al.  Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. , 1998, Catheterization and cardiovascular diagnosis.

[62]  David P Miller,et al.  Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block , 1998, Journal of the American College of Cardiology.

[63]  R. Califf,et al.  Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. , 1997, The American journal of cardiology.

[64]  M. Leon,et al.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. , 1997, The New England journal of medicine.

[65]  E. Topol,et al.  Late myocardial ischemic events after saphenous vein graft intervention--importance of initially "nonsignificant" vein graft lesions. , 1997, The American journal of cardiology.

[66]  W. O’Neill,et al.  Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. , 1996, Catheterization and cardiovascular diagnosis.

[67]  W J Keon,et al.  Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.

[68]  W. O’Neill,et al.  Features and outcome of no-reflow after percutaneous coronary intervention. , 1995, The American journal of cardiology.

[69]  F. Loop,et al.  A 20-year experience in coronary artery reoperation. , 1989, European heart journal.

[70]  M. Trivella,et al.  Coronary effects of adenosine in conscious man. , 1989, European heart journal.

[71]  F. Loop,et al.  Fifteen hundred coronary reoperations. Results and determinants of early and late survival. , 1987, The Journal of thoracic and cardiovascular surgery.

[72]  L. Fisher,et al.  Comparison of operative mortality and morbidity for initial and repeat coronary artery bypass grafting: The Coronary Artery Surgery Study (CASS) registry experience. , 1984, The Annals of thoracic surgery.

[73]  S. Bailey,et al.  CORONARY ARTERY DISEASE Original Studies Use of A Self-Expanding Super-Elastic All-Metal Endoprosthesis; to Treat Degenerated SVG Lesions: The SESAME First in Man Trial , 2010 .

[74]  J. Ornato,et al.  ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Circulation.